Arthritis, a term that encompasses over a hundred different conditions affecting joints and connective tissues, presents a significant health challenge across the globe. Characterized by joint inflammation, commonly referred to as rheumatism, arthritis’s causes range from injury, abnormal metabolism, genetic factors, infections, to an overactive immune system. This comprehensive guide aims to shed light on […]
Alvotech and Teva Pharmaceuticals have achieved a significant milestone with the U.S. Food and Drug Administration’s (FDA) approval of SIMLANDI (adalimumab-ryvk) injection. This approval positions SIMLANDI as an interchangeable biosimilar to Humira, a leading treatment for various arthritis and inflammatory conditions. The approval covers a wide range of conditions, including adult rheumatoid arthritis, juvenile idiopathic […]
Takeda Pharmaceutical Company announced positive results from its Phase 2b clinical trial for TAK-279, an investigational oral TYK2 inhibitor for treating psoriatic arthritis. Meeting its primary endpoint, the study confirmed that TAK-279 improved symptoms significantly better than a placebo at 12 weeks. This news supports TAK-279’s potential as a robust oral treatment for psoriatic arthritis […]
Arthritis, characterized by joint inflammation, can cause immense pain and restrict physical movements, leading to frustration for those affected. However, there are several home remedies that can help manage arthritis and alleviate its symptoms. In this article, we will explore some effective natural remedies for arthritis. Managing your mind as the primary treatment of arthritis […]
Lupin Limited has announced the US launch of authorized generic version of Horizon Pharma Therapeutics’ PENNSAID (Diclofenac Sodium Topical Solution), 2% w/w. Diclofenac Sodium Topical Solution is indicated for the treatment of arthritis of the knee. Citing data from IQVIA MAT October 2022, the Indian pharma company said that the estimated annual sales of Diclofenac […]
Lupin Limited has secured approval from Health Canada for Rymti, the company’s biosimilar to Enbrel (etanercept), an inhibitor of tumour necrosis factor (TNF). Rymti is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis. Lupin said that Rymti is available in Canada as an […]
Chinese biopharma company Bio-Thera Solutions has signed a commercialization and license deal worth up to $150 million with Hikma Pharmaceuticals to commercialize the former’s BAT2206. BAT2206 is a monoclonal antibody, which is being developed by the UK-based pharma company as a biosimilar referencing Jansen’s Stelara (ustekinumab), in the US. Stelara is presently approved for the […]
Dr. Reddy’s Laboratories said that it has relaunched over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, the store-brand equivalent of Bayer HealthCare’s Aleve, in the US market. The relaunch is as per the approval from the US Food and Drug Administration (FDA), said the Indian pharma company. According to Dr. Reddy’s Laboratories, its OTC Naproxen […]
AbbVie said that RINVOQ (upadacitinib, 15 mg, once daily) has met the primary endpoint and key secondary endpoints in the SELECT-CHOICE phase 3 trial in a certain population of rheumatoid arthritis patients. RINVOQ met the primary endpoint of non-inferiority compared to Bristol Myers Squibb’s ORENCIA (abatacept) on change from baseline in Disease Activity Score 28 […]
Antibe Therapeutics, a Canadian pharma company has completed enrollment of patients in a phase 2B dose-ranging, efficacy clinical trial of its lead drug candidate ATB-346 for its use in reducing osteoarthritis (OA) pain. The mid-stage clinical study will assess the effectiveness of ATB-346 in the reduction of OA knee pain in comparison to placebo in […]